$1.86
+0.03 (+1.64%)
Open$1.84
Previous Close$1.83
Day High$1.89
Day Low$1.80
52W High$3.10
52W Low$1.33
Volume—
Avg Volume1.62M
Market Cap164.89M
P/E Ratio—
EPS$-0.43
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+394.6% upside
Current
$1.86
$1.86
Target
$9.20
$9.20
$6.27
$9.20 avg
$10.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 16.73M | 11.12M | 53.79M |
| Net Income | -43,162,398 | -25,819,978 | 2.31M |
| Profit Margin | -258.1% | -245.2% | 4.3% |
| EBITDA | -42,052,353 | -26,553,496 | 4.13M |
| Free Cash Flow | — | — | 1.88M |
| Rev Growth | +50.5% | +50.5% | +4.8% |
| Debt/Equity | 0.32 | 0.32 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |